Dermal Cell News 2.37 October 24, 2016 | |
| |
TOP STORYSkin Adipocyte Stem Cell Self-Renewal Is Regulated by a PDGFA/AKT-Signaling Axis The authors used the dynamic adipogenic program that occurs during hair growth to uncover an unrecognized regulator of adipocyte stem cells self-renewal and proliferation, PDGFA, which activates AKT signaling to drive and maintain the adipogenic program in the skin. [Cell Stem Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DERMAL STEM CELLS & TISSUE REGENERATIONDermal-Epidermal Cross-Talk: Differential Interactions with Microvascular Endothelial Cells Researchers reported that human dermal fibroblasts (NHDF) promote viability and proliferation of microvascular endothelial cells (HMVEC), while HMVEC are not mitogenic for NHDF. [J Cell Physiol] Abstract The role of Wnt agonists/antagonists as mediators of androgen inhibition of dermal papilla cell-induced hair follicle stem cell differentiation was evaluated. [Mol Cell Endocrinol] Abstract Regulation of Srpr Expression by miR-330-5p Controls Proliferation of Mouse Epidermal Keratinocyte The authors investigated the role of SRPR and regulation of its expression by miRNA in skin keratinocytes. [PLoS One] Full Article SKIN CANCERS & DISORDERSScientists identified a previously unsuspected mechanism of BRAF inhibitor resistance driven by elevated Hedgehog pathway activation that is observed in a cohort of melanoma patients after vemurafenib treatment. [Oncogene] Full Article Synergistic Inhibitory Effects of Celecoxib and Plumbagin on Melanoma Tumor Growth Researchers identified that the combinatorial effect of Celecoxib and Plumbagin leads to synergistic killing of cultured melanoma cells compared to normal cells by inhibiting cyclooxygenase-2 and STAT3, which synergistically decreased levels of key cyclins on which the cancer cells were dependent for survival. [Cancer Lett] Abstract Investigators found that over-expression of fas-associated protein with death domain (FADD) or a mutant of FADD, which is truncated of the C-terminal tail (N-FADD) caused apoptosis of B16F10 cells in vitro, even more, N-FADD showed a more potent apoptotic effect than FADD. [Sci Rep] Full Article Researchers examined the feasibility of antisense oligonucleotide-mediated exon skipping in vitro in primary cultured keratinocytes and fibroblasts, and systemically in vivo using a human skin-graft mouse model. [Mol Ther Nucleic Acids] Full Article The relationship between PD-L1 with specific monoclonal antibodies tumor exposition and anti-tumor effect represents a challenge that scientists addressed in this work through the identification of certain biomarkers implicated in the antibody’s mechanism of action, using a syngeneic melanoma mouse model. [Oncotarget] Full Article Researchers deciphered new connections between insulin-like growth factor-1 (IGF-1) and stemness features and identified IGF-1 as instrumental for maintaining the melanoma-initiating cells phenotype. [Oncotarget] Full Article | |
| |
REVIEWSIn the Wnt-Er of Life: Wnt Signaling in Melanoma and Aging The authors review the current literature addressing the roles of different Wnt pathways in melanoma pathogenesis, provide an overview of Wnt signaling during aging, and discuss the intersection between melanoma and aging in terms of Wnt signaling. [Br J Cancer] Full Article Inflammatory Regulation of Stem-Like Cells in Melanoma Researchers discuss the characterization of cancer stem cells and describe their modulation by inflammation with a focus on melanoma. [Melanoma Res] Abstract Visit our reviews page to see a complete list of reviews in the dermal cell research field. | |
| |
INDUSTRY NEWSLigand Pharmaceuticals Incorporated partner Melinta Therapeutics announced that it has submitted New Drug Applications to the U.S. Food and Drug Administration for approval of IV and oral Baxdela™ for the treatment of patients with acute bacterial skin and skin structure infections. [Ligand Pharmaceuticals, Inc.] Press Release Trevi Therapeutics Announces Positive Results from Phase II Trial in Prurigo Nodularis Trevi Therapeutics, Inc. announced positive results from its Phase II trial for the treatment of moderate to severe prurigo nodularis. Prurigo nodularis, a severely pruritic dermatological condition characterized by itchy skin papules and nodules, has significant impact on quality of life and has no approved therapies. [Trevi Therapeutics, Inc. (Business Wire, Inc.)] Press Release | |
| |
POLICY NEWSReview Finds Misconduct in Events Surrounding WHO Fetal Growth Study For the first time in its 68-year history, the World Health Organization (WHO) has concluded that researchers are guilty of research misconduct. An independent review commissioned by WHO has found that “research ethics misconduct occurred” in a multimillion-dollar global study on fetal growth led by researchers at the University of Oxford in the United Kingdom. [ScienceInsider] Editorial Two Major California Research Institutes Will Merge One of the biggest nonprofit biomedical research outfits in the world is getting a new translational medicine research arm, aimed at speeding the conversion of basic research insights into novel medicines. Officials at the Scripps Research Institute announced that it will merge with the California Institute for Biomedical Research, which was launched in 2012 as a nonprofit version of a drug development company. [ScienceInsider] Editorial To Save Money, NSF Requires University Cost-Sharing for Rotators The National Science Foundation (NSF) has decided that universities should pay 10% of the salaries of faculty members working temporarily at the agency. NSF hopes the new policy will demonstrate its commitment to saving taxpayer dollars without alienating the academic community that it relies upon to stay on the cutting edge of basic science. [ScienceInsider] Editorial
| |
EVENTSNEW Global Forum on Transplantation Research and Technologies Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – 3D Bioprinting (Inserm) NEW Postdoctoral Position – Immunobiology of Stromal Cells (Institut Pasteur) Clinical Trials Fellow – Dermatology (Brigham and Women’s Hospital) Scientific Director – Global Medical Affairs (Celgene Corporation) Postdoctoral Researcher – Transplantation Immunology (Nuffield Department of Surgical Sciences) Pluripotent Stem Cell Faculty (Stanford University) Postdoctoral Fellowship – Non-Melanoma Skin Cancer (Brigham and Women’s Hospital) Postdoctoral Researcher – Skin Immunology (University Hospital Lausanne) Postdoctoral Fellow – Melanoma Biology (Icahn School of Medicine) Postdoctoral Scholar – Cancer Biology (The Pennsylvania State University College of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Dermal Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Dermal Cell News Volume 2.37 | Oct 24 2016